CenterBook Partners LP Purchases 122,894 Shares of NewAmsterdam Pharma (NASDAQ:NAMS)

CenterBook Partners LP increased its position in shares of NewAmsterdam Pharma (NASDAQ:NAMS) by 143.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 208,589 shares of the company’s stock after acquiring an additional 122,894 shares during the quarter. CenterBook Partners LP owned about 0.23% of NewAmsterdam Pharma worth $5,361,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in NAMS. Jennison Associates LLC lifted its position in NewAmsterdam Pharma by 291.9% during the 4th quarter. Jennison Associates LLC now owns 3,998,541 shares of the company’s stock valued at $102,763,000 after purchasing an additional 2,978,263 shares during the period. Wellington Management Group LLP raised its stake in shares of NewAmsterdam Pharma by 2,410.4% during the fourth quarter. Wellington Management Group LLP now owns 2,315,123 shares of the company’s stock worth $59,499,000 after buying an additional 2,222,900 shares during the last quarter. Alliancebernstein L.P. acquired a new position in NewAmsterdam Pharma in the fourth quarter valued at approximately $47,752,000. TimesSquare Capital Management LLC boosted its stake in NewAmsterdam Pharma by 250.9% in the fourth quarter. TimesSquare Capital Management LLC now owns 895,574 shares of the company’s stock valued at $23,016,000 after acquiring an additional 640,329 shares during the last quarter. Finally, Frazier Life Sciences Management L.P. grew its holdings in NewAmsterdam Pharma by 5.1% during the 3rd quarter. Frazier Life Sciences Management L.P. now owns 12,855,194 shares of the company’s stock worth $213,396,000 after acquiring an additional 628,251 shares during the period. Institutional investors own 89.89% of the company’s stock.

NewAmsterdam Pharma Price Performance

NASDAQ:NAMS opened at $15.16 on Wednesday. The business’s 50-day simple moving average is $20.76 and its 200-day simple moving average is $21.30. NewAmsterdam Pharma has a fifty-two week low of $14.06 and a fifty-two week high of $27.29. The stock has a market capitalization of $1.66 billion, a PE ratio of -5.83 and a beta of -0.01.

NewAmsterdam Pharma (NASDAQ:NAMS) last announced its earnings results on Wednesday, February 26th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.47). The business had revenue of $12.77 million for the quarter, compared to analysts’ expectations of $3.30 million. On average, research analysts expect that NewAmsterdam Pharma will post -1.75 earnings per share for the current year.

Insider Activity at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, Director James N. Topper acquired 4,005 shares of the business’s stock in a transaction dated Tuesday, March 4th. The shares were acquired at an average price of $21.02 per share, with a total value of $84,185.10. Following the completion of the transaction, the director now directly owns 3,012,434 shares in the company, valued at $63,321,362.68. This trade represents a 0.13 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CAO Louise Frederika Kooij sold 150,000 shares of the firm’s stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $20.37, for a total transaction of $3,055,500.00. Following the completion of the transaction, the chief accounting officer now directly owns 15,000 shares of the company’s stock, valued at approximately $305,550. This trade represents a 90.91 % decrease in their position. The disclosure for this sale can be found here. 19.50% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on NAMS. HC Wainwright reissued a “buy” rating and issued a $48.00 price target on shares of NewAmsterdam Pharma in a research note on Tuesday, January 14th. Scotiabank increased their target price on NewAmsterdam Pharma from $47.00 to $52.00 and gave the company a “sector outperform” rating in a research note on Thursday, February 27th. Needham & Company LLC restated a “buy” rating and set a $42.00 target price on shares of NewAmsterdam Pharma in a research report on Tuesday. UBS Group set a $41.00 price target on shares of NewAmsterdam Pharma in a research report on Monday, March 3rd. Finally, Royal Bank of Canada restated an “outperform” rating and set a $40.00 price objective on shares of NewAmsterdam Pharma in a report on Friday, January 24th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, NewAmsterdam Pharma has a consensus rating of “Buy” and an average target price of $43.33.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.